FME · Fresenius Medical Care AG · Financials
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Browse captured authority reports and their original financial labels
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR | — | 618.14M | 660.43M | 706.4M | 800.88M | 770.72M | — | — | — | — | — | — | — | — | — | — |
| EUR | — | 2.41B | 2.48B | 2.49B | 2.37B | 2B | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | $3.04B | $2.9B | $2.64B | $2.38B | $2.22B | $2B | $1.82B | $1.99B | $1.88B | $1.71B | |
| — | — | — | — | — | — | $118.43M | $110.36M | $98.48M | $93.1M | $87.44M | $77.85M | — | — | — | — | |
| — | — | — | — | — | — | $46.64M | $116.58M | $84.24M | $38.94M | $44.47M | $59.83M | $25.41M | $21.4M | $24.81M | $28.59M | |
| $0 | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | — | — | |
| — | — | — | — | — | — | -$64.91M | -$31.45M | -$24.84M | -$26.11M | -$17.44M | -$30.96M | -$8.95M | $4.53M | — | — | |
| — | — | — | — | — | — | $305.58M | $283.7M | $214.54M | $145.73M | $140.17M | $106.11M | $86.88M | $74.08M | $42.38M | $38.18M | |
| — | — | — | — | — | — | $1.26B | $780.89M | $508.11M | $1.05B | $1.18B | $779.43M | $834.2M | $992.7M | $565.45M | $823.42M | |
| USD/shares | — | — | — | — | — | — | $4.07 | $3.38 | $3.46 | $3.65 | $3.89 | $3.54 | $3.25 | $2.99 | $2.75 | $2.43 |
| USD/shares | — | — | — | — | — | — | $4.06 | $3.38 | $3.45 | $3.65 | $3.87 | $3.51 | $3.24 | $2.99 | $2.74 | $2.42 |
| shares | — | — | — | — | — | — | 305.75M | 304.44M | 302.34M | 301.88M | 301.14M | 299.01M | 296.81M | 294.42M | 293.23M | — |
| shares | — | — | — | — | — | — | 306.26M | 304.92M | 302.87M | 302.55M | 302.9M | 300.81M | 298.12M | 294.42M | 294.01M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: 1.65B in buybacks, 1.81B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of long-term borrowings | 2026-06-30 | EUR 1,276,730,000 | 6-K filed 2026-08-04 |
| Noncurrent long-term borrowings | 2026-06-30 | EUR 5,824,532,000 | 6-K filed 2026-08-04 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.